Page 6,984«..1020..6,9836,9846,9856,986..6,9907,000..»

Pharmaceutical Strategies Group Acquires Artemetrx

Posted: Published on March 20th, 2012

PLANO, Texas--(BUSINESS WIRE)-- Pharmaceutical Strategies Group, LLC (PSG), Americas largest independent pharmacy benefits consulting firm, has closed on its acquisition of Artemetrx Health Resources, the company announced today. Terms of the transaction were not disclosed. Artemetrx, whose technology was originally developed at the University of Kentucky, offers data analytic tools and clinical programs that integrate pharmacy, medical, and other healthcare information. PSGs clients have increasingly indicated their desire to have a more comprehensive view of patients clinical profiles in managing the prescription drug benefit. It is increasingly difficult to get a clear picture of why a medication is being used and to capture the total cost of care by just reviewing prescription claims data alone. This need is particularly acute for specialty medications, where 50% or more of the drug spend is not billed as a prescription, but as a medical claim, said Dave Borden, CEO of PSG. Joining PSG will be the senior management team of Artemetrx led by Dr. Brenda Motheral, Artemetrx's President, and Dr. John Langefeld, Chief Medical Officer. Dr. Motheral brings with her more than 15 years of experience in healthcare analytics and clinical program development, both in the pharmacy benefits management (PBM) and disease management … Continue reading

Posted in Pharmacy | Comments Off on Pharmaceutical Strategies Group Acquires Artemetrx

Regence Rx and Catalyst Health Solutions Announce Pharmacy Benefit Management Agreement Through 2017

Posted: Published on March 20th, 2012

PORTLAND, Ore. & ROCKVILLE, Md.--(BUSINESS WIRE)-- Regence Rx, Inc. and Catalyst Health Solutions, Inc., (NASDAQ: CHSI - News) today announced an agreement that establishes Catalyst Rx as the exclusive provider of pharmacy benefit management (PBM) services for Regence Rx. The agreement is expected to be effective May 1, 2012 and the initial term runs through December 31, 2017 with a four-year optional extension. Through this agreement, Regence Rx will carve out its operational functions, and transfer related people, technology, and internal client service assets to Catalyst for them to manage and operate. Regence Rx will continue to provide clinical and contracting support to its customers. Catalyst Rx is a full-service PBM that serves more than 18 million lives in the United States and Puerto Rico. This agreement will allow Regence Rx to leverage the scale and expertise of Catalyst Rx, one of the countrys fastest growing PBMs, and its national provider network as the two organizations partner to deliver more efficient pharmacy benefit programs and better clinical outcomes for clients and individuals throughout the Pacific Northwest and Intermountain State Regions. Regence Rx currently provides PBM services for more than 1.2 million members of Regence Health Plans and provides related services … Continue reading

Posted in Pharmacy | Comments Off on Regence Rx and Catalyst Health Solutions Announce Pharmacy Benefit Management Agreement Through 2017

Hero Dog Receives Stem Cell Therapy

Posted: Published on March 20th, 2012

Stem Cell Therapy Helping Heroic Dogs Recover News4's Darcy Spencer explains how a breakthrough treatment is helping search and rescue dogs like Red recover after years of working in disaster zones. A breakthrough treatment is helping area search-and-rescue dogs that played key roles on Sept. 11, 2001, and during other disasters. Red's first assignment as a search, rescue and recovery dog was at the Pentagon following the 9/11 attacks. Years of rescue work and a 12-foot fall from a ladder have taken a toll. Arthritis forced Red into retirement in July and turned her into a couch potato. The 12-year-old black lab received a breakthrough stem cell treatment today that will ease her pain and give her more mobility. Her veterinarian, Dr. John Herrity, of the Burke Animal Clinic, has done more than two dozen of the stem cell operations developed by Medivet America, which also donated the cost of the procedure. The treatment won't bring Red back out of retirement, but it is expected to put spring back in her step within a couple of months. Two other 9/11 search-and-rescued dogs have been treated with stem cell therapy and are back to their normal activities. Original post: Hero Dog … Continue reading

Comments Off on Hero Dog Receives Stem Cell Therapy

Cryo-Save Group N.V.: Revenue up 4% to €41.9 million

Posted: Published on March 20th, 2012

Cryo-Save Group N.V. (Euronext: CRYO, `Cryo-Save`, or `the Group`), the leading international stem cell storage brand and the largest family stem cell bank in Europe, has published its financial results for the year ended 31 December 2011. Financial highlights Revenue up 4% to 41.9 million (2010: 40.4 million) Operating expenses before depreciation and amortisation increased with 1.6 million mainly due to further investments in Cryo-Lip (0.8 million) and acquisition impact (0.7 million) EBITDA*: 6.3 million (2010: 7.3 million) EBITA**: 4.5 million (2010: 5.8 million) Operating profit: 2.9 million (2010: 4.5 million) Profit before taxation: 3.0 million (2010: 3.9 million) Net profit: 2.3 million (2010: 2.6 million) Basic earnings per share 25.0 euro cents (2010: 27.6 euro cents) Robust net cash from operating activities 6.2 million (2010: 2.8 million) Solid cash position of 7.0 million as at 31 December 2011 (2010: 6.0 million) Dividend per share of 0.08, up 14% (2010: 0.07) * EBITDA is defined as Earnings Before Interest, Taxation Depreciation and Amortisation ** EBITA is defined as Earnings Before Interest, Taxation and Amortisation of identified intangible assets Operational highlights 39,900 new samples stored in 2011, up 4% compared to previous year (2010: 38,300). Of these, 25,200 were new cord … Continue reading

Comments Off on Cryo-Save Group N.V.: Revenue up 4% to €41.9 million

9/11 Search And Rescue Dog Gets Stem Cell Treatment

Posted: Published on March 20th, 2012

BURKE, Va. (WUSA) -- Red, a black lab from Annapolis, has spent the last ten years as a search and rescue dog. Her missions have included Hurricane Katrina, the La Plata tornadoes, and the Pentagon after 9/11. "The search and rescue dogs at the Pentagon are credited with finding 70% of the human remains," said Heather Roche, Red's owner and handler. "That helped a whole lot of those families actually get closure." At just under two years old, 9/11 was Red's first search. Today, she's one of the last 9/11 search and rescue dogs still alive. She retired last July due to severe arthritis. "The last few months, she would like to be a couch potato but she can't even get on the couch any more," said Roche. "It would be nice if she could do those kinds of things that she misses." Roche brought Red to the Burke Animal Clinic for stem cell regenerative therapy compliments of MediVet America, the company that developed the in-clinic stem cell technology. "This is a small something that we can give back as a way of saying thanks for what you guys have done for us," said Dr. John Herrity at the Burke … Continue reading

Comments Off on 9/11 Search And Rescue Dog Gets Stem Cell Treatment

State: Second doctor's license restricted for performing stem cell treatment on patient who died

Posted: Published on March 20th, 2012

Dr. Konstantine K. Yankopolus The state Department of Health restricted a second doctor's license for working under the direction of Dr. Zannos Grekos in performing a stem cell treatment and for falsifying a medical report after a patient died, according to the state order. The emergency license restriction is against Dr. Konstantine K. Yankopolus, 3880 Colonial Blvd., Suite 2, Fort Myers, according to the order issued by the state health department late Monday. The restriction only prohibits Yankopolus from doing anything with stem cells. After a career as an obstetrician/gynecologist, he is now in general practice. "We attempted a life-saving procedure on a very sick patient and it didn't go well," Yankopolus said Monday night. "Our motivation was pure the patient had no other option." The state's action comes on the heels of Grekos attorney last week issuing a statement that another doctor, and not his client, was involved in the treatment of a 77-year-old Indiana man who died March 2. Grekos attorney also denied that a stem cell treatment was performed, only liposuction. The state health department suspended Grekos license after the death, saying Grekos violated an earlier restriction that he not to do anything with stem cells or … Continue reading

Comments Off on State: Second doctor's license restricted for performing stem cell treatment on patient who died

Huntington's Disease – Stem Cell Therapy Potential

Posted: Published on March 20th, 2012

Editor's Choice Academic Journal Main Category: Huntingtons Disease Also Included In: Stem Cell Research Article Date: 19 Mar 2012 - 10:00 PDT email to a friend printer friendly opinions Current Article Ratings: 4 (1 votes) 3 (1 votes) However, according to a study published March 15 in the journal Cell Stem Cell, a special type of brain cell created from stem cells could help restore the muscle coordination deficits that are responsible for uncontrollable spasms, a characteristic of the disease. The researchers demonstrated that movement in mice with a Huntington's-like condition could be restored. Su-Chun Zhang, a University of Wisconsin-Madison neuroscientist and the senior author of the study, said: In the study Zhang, who is an expert in creating various types of brain cells from human embryonic or induce pluripotent stem cells, and his team focused on GABA neurons. The degradation of GABA cells causes the breakdown of a vital neural circuit and loss of motor function in individuals suffering from Huntington's disease. According to Zhang, GABA neurons generate a vital neurotransmitter, a chemical that helps support the communication network in the brain that coordinates movement. Zhang and his team at the UW-Madison Waisman Center, discovered how to generate large … Continue reading

Comments Off on Huntington's Disease – Stem Cell Therapy Potential

Rhenovia launches drug discovery for Huntington's disease

Posted: Published on March 20th, 2012

Rhenovia Pharma of Cambridge and Mulhouse, France has initiated drug research programs in rare, orphan and neglected diseases, beginning with Huntingtons disease (HD) and Duchenne muscular dystrophy (DMD), according to a written announcement from the company. The company works to develop new medications to treat neurodegenerative, neurological and psychiatric diseases. As a first step, Rhenovia is building a new biosimulation platform aimed at modeling the complex interplay between biological mechanisms in striatum, the brain region that is most affected in Huntingtons disease. HD is a fatal, rare neurodegenerative disease that is particularly difficult to treat because of the very broad spectrum of symptoms it causes, involving involuntary movement disorders, cognitive deficits and psychiatric manifestations, according to the company. It is exactly because of this variety and often opposite syndromes that the biosimulation approach is probably the most appropriate strategy in the search for new treatments, said Serge Bischoff, president and CEO of Rhenovia. It will allow us to integrate the complexity of the biological systems affected by HD and to address the multifactorial nature of this disease. Rare diseases are defined as those affecting fewer than one in 2,000, 80 percent of which are caused by genetic defects. They also … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Rhenovia launches drug discovery for Huntington's disease

Newborn screening for DMD shows promise as an international model

Posted: Published on March 20th, 2012

Public release date: 19-Mar-2012 [ | E-mail | Share ] Contact: Erin Pope Erin.Pope@NationwideChildrens.org 614-355-0495 Nationwide Children's Hospital Investigators at Nationwide Children's Hospital, working with the DNA Sequencing Core Facility at the University of Utah, have developed an approach to newborn screening (NBS) for the life-threatening genetic disorder, Duchenne muscular dystrophy (DMD) and potentially other muscular dystrophies. As a model for NBS, the approach published online in January in the Annals of Neurology provides evidence that this approach could be implemented if approved by regulatory bodies at a state level or alternatively through the Secretary's Advisory Committee on Heritable Disorders in Newborns and Children. DMD is the most common, severe childhood form of muscular dystrophy, inherited as an X-linked recessive disorder. Progressive muscle weakness with loss of ambulation by 12-to-13 years of age is the expected outcome. Heart involvement is significant and may require treatment to avert premature death. On average, patients are diagnosed with DMD at 5 years of age, although parents often notice impaired motor skills at an earlier age. Over the last three decades, creatine kinase (CK) testing on dried blood spots has been attempted as a method for newborn screening for DMD. CK is an enzyme … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Newborn screening for DMD shows promise as an international model

Newborn Screening for Duchenne Muscular Dystrophy Shows Promise as an International Model

Posted: Published on March 20th, 2012

Newswise Investigators at Nationwide Childrens Hospital, working with the DNA Sequencing Core Facility at the University of Utah, have developed an approach to newborn screening (NBS) for the life-threatening genetic disorder, Duchenne muscular dystrophy (DMD) and potentially other muscular dystrophies. As a model for NBS, the approach published online in January in the Annals of Neurology provides evidence that this approach could be implemented if approved by regulatory bodies at a state level or alternatively through the Secretarys Advisory Committee on Heritable Disorders in Newborns and Children. DMD is the most common, severe childhood form of muscular dystrophy, inherited as an X-linked recessive disorder. Progressive muscle weakness with loss of ambulation by 12-to-13 years of age is the expected outcome. Heart involvement is significant and may require treatment to avert premature death. On average, patients are diagnosed with DMD at 5 years of age, although parents often notice impaired motor skills at an earlier age. Over the last three decades, creatine kinase (CK) testing on dried blood spots has been attempted as a method for newborn screening for DMD. CK is an enzyme that leaks into the blood from damaged muscle cells; it is markedly elevated in DMD and some … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Newborn Screening for Duchenne Muscular Dystrophy Shows Promise as an International Model

Page 6,984«..1020..6,9836,9846,9856,986..6,9907,000..»